103 related articles for article (PubMed ID: 31986004)
1. Programing Assembling/Releasing Multifunctional miRNA Nanomedicine to Treat Prostate Cancer.
Ma D; Liu H; Zhao P; Ye L; Zou H; Zhao X; Dai H; Kong X; Liu P
ACS Appl Mater Interfaces; 2020 Feb; 12(8):9032-9040. PubMed ID: 31986004
[TBL] [Abstract][Full Text] [Related]
2. Cationic Polymer Nanoparticles-Mediated Delivery of miR-124 Impairs Tumorigenicity of Prostate Cancer Cells.
Conte R; Valentino A; Di Cristo F; Peluso G; Cerruti P; Di Salle A; Calarco A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013257
[TBL] [Abstract][Full Text] [Related]
3. Tailored design of multifunctional and programmable pH-responsive self-assembling polypeptides as drug delivery nanocarrier for cancer therapy.
Wang TW; Yeh CW; Kuan CH; Wang LW; Chen LH; Wu HC; Sun JS
Acta Biomater; 2017 Aug; 58():54-66. PubMed ID: 28606810
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment.
Cho HS; Dong Z; Pauletti GM; Zhang J; Xu H; Gu H; Wang L; Ewing RC; Huth C; Wang F; Shi D
ACS Nano; 2010 Sep; 4(9):5398-404. PubMed ID: 20707381
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells.
He M; Liu Y; Deng X; Qi S; Sun X; Liu G; Liu Y; Liu Y; Zhao M
Prostate; 2013 Jul; 73(10):1048-56. PubMed ID: 23389960
[TBL] [Abstract][Full Text] [Related]
6. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
Gan L; Yin ZF; Li M
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):419-21. PubMed ID: 18581899
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
Pu YS; Hsieh MW; Wang CW; Liu GY; Huang CY; Lin CC; Guan JY; Lin SR; Hour TC
Biochem Pharmacol; 2006 Mar; 71(6):751-60. PubMed ID: 16413505
[TBL] [Abstract][Full Text] [Related]
8. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence.
Hernes E; Fosså SD; Berner A; Otnes B; Nesland JM
Br J Cancer; 2004 Jan; 90(2):449-54. PubMed ID: 14735192
[TBL] [Abstract][Full Text] [Related]
9. PEG-Poly(amino acid)s/MicroRNA Complex Nanoparticles Effectively Arrest the Growth and Metastasis of Colorectal Cancer.
Wang Y; Costanza F; Li C; Nimmagadda A; Song D; Cai J
J Biomed Nanotechnol; 2016 Jul; 12(7):1510-19. PubMed ID: 29337490
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
Jia RP; Xu LW; Su Q; Zhao JH; Li WC; Wang F; Xu Z
Asian J Androl; 2008 Sep; 10(5):758-64. PubMed ID: 18645679
[TBL] [Abstract][Full Text] [Related]
11. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.
Wu X; Tai Z; Zhu Q; Fan W; Ding B; Zhang W; Zhang L; Yao C; Wang X; Ding X; Li Q; Li X; Liu G; Liu J; Gao S
Int J Nanomedicine; 2014; 9():5431-40. PubMed ID: 25473281
[TBL] [Abstract][Full Text] [Related]
12. Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells.
Thamilselvan V; Menon M; Stein GS; Valeriote F; Thamilselvan S
J Cell Biochem; 2017 Dec; 118(12):4331-4340. PubMed ID: 28430389
[TBL] [Abstract][Full Text] [Related]
13. Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1.
Xu B; Huang Y; Niu X; Tao T; Jiang L; Tong N; Chen S; Liu N; Zhu W; Chen M
Prostate; 2015 Dec; 75(16):1896-903. PubMed ID: 26306811
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
[TBL] [Abstract][Full Text] [Related]
15. Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.
Xu S; Wu X; Tao Z; Li H; Fan C; Chen S; Guo J; Ning Y; Hu X
Genes Genomics; 2020 Mar; 42(3):299-307. PubMed ID: 31872382
[TBL] [Abstract][Full Text] [Related]
16. Using ligands to target cancer cells.
Farokhzad OC
Clin Adv Hematol Oncol; 2012 Aug; 10(8):543-4. PubMed ID: 23073055
[No Abstract] [Full Text] [Related]
17. NGF/γ-IFN inhibits androgen-independent prostate cancer and reverses androgen receptor function through downregulation of FGFR2 and decrease in cancer stem cells.
Chen W; Wang GM; Guo JM; Sun LA; Wang H
Stem Cells Dev; 2012 Dec; 21(18):3372-80. PubMed ID: 22731611
[TBL] [Abstract][Full Text] [Related]
18. A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA.
Zhang T; Xue X; He D; Hsieh JT
Cancer Lett; 2015 Sep; 365(2):156-65. PubMed ID: 26054847
[TBL] [Abstract][Full Text] [Related]
19. Targetable Clinical Nanoparticles for Precision Cancer Therapy Based on Disease-Specific Molecular Inflection Points.
Kaittanis C; Bolaender A; Yoo B; Shah N; Ouerfelli O; Grimm J
Nano Lett; 2017 Nov; 17(11):7160-7168. PubMed ID: 29035540
[TBL] [Abstract][Full Text] [Related]
20. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
